Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non-Small-Cell Lung Cancer

This small cohort study suggests that a 14-gene prognostic assay more accurately stratifies risk among early-stage NSCLC patients than current NCCN criteria. NCCN guidelines already advocate risk stratification within tumor, node, metastases stages. This molecular assay has clinical utility in better identifying high-risk patients and might improve NCCN adjuvant chemotherapy recommendations.